finance.yahoo.com ·
Azenta Q2 Earnings Call Highlights
Topic context
This topic has been covered 391776 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedAzenta's weak Q2 results reflect execution shortfalls and cautious demand in North America for life sciences tools and services. The $149M impairment signals reduced growth expectations for Multiomics and Sample Management Solutions segments. No direct commodity or supply chain scarcity; impact is company-specific and sector-wide demand softness.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Azenta Q2 FY2026 revenue $145M, up 1% YoY, organic revenue down 3%.
- Non-GAAP loss $0.04/share; adjusted EBITDA margin 5.4%.
- Non-cash impairments $149M for Multiomics and Sample Management Solutions.
- Revised FY2026 revenue guidance to $603M-$621M.
- Cash $565M, no debt.
Mid-term demand recovery is uncertain; Azenta's impairments indicate lower growth expectations. Window: 2-4 weeks.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- GLOBAL_HEALTHCAREmid
Related stories
finance.yahoo.com
Health Tech Q1 2026 Earnings
finance.yahoo.com
Ncmi Q1 2026 Earnings Transcript
finance.yahoo.com
Transcript Valneva Q1 2026 Earnings
zerohedge.com
Europe Primed Lower Open Amid Lack Progress Usiran Hefty Speaker Slate Nvidia Earnings Due
timesofindia.indiatimes.com